{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-183719","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2025-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.496825+00:00","generated_at":"2026-05-17T11:05:25.937393+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enanta sues Pfizer in EU UPC for Paxlovid patent infringement","bullets":["Filed suit in Unified Patent Court (action 35071/2025) alleging Pfizer's Paxlovid infringes European Patent EP 4 051 265.","Action covers 18 EU countries participating in UPC; patent based on July 2020 application for coronavirus protease inhibitors.","European counterpart of US Patent 11,358,953, which is already subject to ongoing US litigation between Enanta and Pfizer.","Hearing expected within 12-month UPC target; decision within weeks thereafter, subject to appeal.","No damages determination yet; if infringement found, separate proceedings would assess damages."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-183719","json":"https://secwatch.observer/filing/0001193125-25-183719.json","markdown":"https://secwatch.observer/filing/0001193125-25-183719.md","text":"https://secwatch.observer/filing/0001193125-25-183719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000119312525183719/0001193125-25-183719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000119312525183719/enta-20250820.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:05:25.937393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}